Stratatech Corporation is a regenerative medicine company focused on the commercialization of unique, proprietary skin substitute products for therapeutic and research uses. The company was founded in 2000 to commercialize an extraordinary discovery made at the University of Wisconsin-Madison. Stratatech was acquired by Mallinckrodt, a U.K. pharmaceutical firm, in 2016.
FDA application submitted for Stratatech tissue to treat burns
Stratatech, a Madison company developing regenerative tissue as an alternative to skin grafts in treating burns, has submitted a biologics license application to the Food and Drug Administration, the company said Tuesday.
Stratatech expands facility for making skin tissue for severe burn patients
By Erik Lorenzsonn Mallinckrodt, a global pharmaceutical company, unveiled its expanded production facility for StrataTech's lab-grown skin tissue therapy last week. Photo by ERIK LORENZSONN One of the city's largest and oldest bioscience operations has unveiled an...
Stratatech Gets $26M More to Develop Skin Tissue for Treating Burns
Jeff Buchanan October 16th, 2018 @_jeffbuchanan @xconomy Like Us Xconomy Wisconsin — An agency within the U.S. Department of Health and Human Services has awarded Stratatech, a Madison, WI-based maker of human skin tissue, $26 million in new funding. Stratatech, which...